Your browser doesn't support javascript.
loading
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla, Ivan; Wilson, Michelle K; Clarke, Blaise A; Hirte, Hal W; Welch, Stephen A; Mackay, Helen J; Biagi, Jim J; Reedijk, Michael; Weberpals, Johanne I; Fleming, Gini F; Wang, Lisa; Liu, Geoffrey; Zhou, Chen; Blattler, Chantale; Ivy, S Percy; Oza, Amit M.
Affiliation
  • Diaz-Padilla I; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Wilson MK; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Clarke BA; Department of Laboratory Medicine, University of Toronto, Toronto, Canada.
  • Hirte HW; Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
  • Welch SA; Division of Medical Oncology, London Regional Cancer Program, London, Ontario, Canada.
  • Mackay HJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Biagi JJ; Department of Oncology, Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada.
  • Reedijk M; Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Toronto, Ontario, Canada.
  • Weberpals JI; Division of Gynecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Fleming GF; The University of Chicago Medical Center, Chicago, IL, USA.
  • Wang L; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Liu G; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Zhou C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Blattler C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Ivy SP; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Rockville, MD, USA.
  • Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: amit.oza@uhn.ca.
Gynecol Oncol ; 137(2): 216-22, 2015 May.
Article in En | MEDLINE | ID: mdl-25769658
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Benzazepines / Neoplasms, Glandular and Epithelial Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: America do norte Language: En Journal: Gynecol Oncol Year: 2015 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Benzazepines / Neoplasms, Glandular and Epithelial Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: America do norte Language: En Journal: Gynecol Oncol Year: 2015 Type: Article Affiliation country: Canada